Last reviewed · How we verify
Antidepressant Drug Therapy
Antidepressant drug therapy works by modulating neurotransmitter levels in the brain to alleviate symptoms of depression.
Antidepressant drug therapy works by modulating neurotransmitter levels in the brain to alleviate symptoms of depression. Used for Major depressive disorder.
At a glance
| Generic name | Antidepressant Drug Therapy |
|---|---|
| Also known as | Sertraline, "Zoloft" |
| Sponsor | University of Washington |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Mental Health |
| Phase | Phase 3 |
Mechanism of action
This is a broad category rather than a single drug, encompassing multiple classes (SSRIs, SNRIs, tricyclics, MAOIs, etc.) that increase availability of serotonin, norepinephrine, or dopamine in synaptic spaces. The exact mechanism depends on the specific antidepressant class employed in the University of Washington phase 3 trial, but generally involves reuptake inhibition or monoamine oxidase inhibition to enhance mood regulation and emotional processing.
Approved indications
- Major depressive disorder
Common side effects
- Nausea
- Headache
- Sexual dysfunction
- Insomnia or somnolence
- Weight gain or loss
Key clinical trials
- Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE. (PHASE2)
- The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes Zoster (NA)
- Pharmacogenetic-Guided Antidepressant Treatment in Depression (NA)
- Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder (PHASE2)
- SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety (PHASE2)
- Psilocybin for Treatment-Resistant Depression in Autism (PHASE1)
- A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder (PHASE2)
- Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antidepressant Drug Therapy CI brief — competitive landscape report
- Antidepressant Drug Therapy updates RSS · CI watch RSS
- University of Washington portfolio CI